Clinical development of the GnRH agonist leuprolide acetate depot
Year: 2022
Type: article
Abstract: Leuprolide acetate is the first GnRH agonist that entered clinical development after the discovery of the native GnRH. Several long-acting depot formulations of leuprolide acetate (ranging from 1-month to 6-month intramuscular injections) have been successively developed for various suppressive treatments in men, women, and children, which are available in the United States and globally. This mini review aims to summarize the key clinical studies that led to regulatory approval of leuprolide acetate depot suspension for injection.
Source: F&S Reports
Author: Kristof Chwalisz
Institution: Michigan State University
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,000
Funder: Michigan State University
OpenAlex ID: W4309761353
